3B Pharmaceuticals
  • Targeted Radiotherapy
    • Pipeline
      • Pipeline Chart
      • 3BP Assets
      • Clinical Trials
      • Indications
    • About Nuclear Medicine
      • Imaging
      • Therapy
      • Theragnostics
    • Technology
      • Radiopharmaceuticals
      • Isotopes
    • Publications
    • Partnering
  • About us
    • Team
    • Contact
    • Directions
  • News
  • Careers
  • Search
  • Menu Menu
Blog - Latest News
You are here: Home1 / 2 / 20221222 3BP company statement re Clovis and FAP 2286
22. December 2022/by Jan Michel

20221222 3BP company statement re Clovis and FAP 2286

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png 0 0 Jan Michel https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png Jan Michel2022-12-22 17:05:432022-12-22 17:05:4320221222 3BP company statement re Clovis and FAP 2286
  • © 3B Pharmaceuticals
  • Imprint
  • Data privacy statement

3B Pharmaceuticals GmbH
Magnusstraße 11
D-12489 Berlin
Tel: +49 (0)30 / 63 92 - 43 17
Fax: +49 (0)30 / 63 92 - 43 16
info@3b-pharma.com

Scroll to top